MedPath

Breathe: Slow Paced Breathing to Lower Blood Pressure

Not Applicable
Completed
Conditions
High Blood Pressure
Interventions
Device: RESPeRATE
Behavioral: Guided Breathing
Registration Number
NCT00328016
Lead Sponsor
National Institute on Aging (NIA)
Brief Summary

The purpose of this study is to investigate the nature of the physiological reasons for the decreases in resting blood pressure that can result from systematic practice of computer-guided breathing exercises or meditative relaxation.

Detailed Description

In this randomized clinical trial, persons with moderately elevated blood pressure were trained in either computer-guided breathing exercises or meditative relaxation to breathing. The computer-guided breathing exercise involves listening to tones of ascending and descending pitch to which breathing is entrained to low frequencies over a 15 minute interval. The meditative relaxation involves passive attention to natural breathing for the same duration. Participants will perform these breathing exercises daily at home for four weeks. Before and after the intervention, respiratory, cardiovascular, and urinary endogenous digitalis-like factors will be systematically recorded to determine the extent to which chronic neuroendocrine changes underlie the reductions in blood pressure.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
44
Inclusion Criteria
  • Over 21 years
  • Systolic blood pressure 130-160 or diastolic blood pressure 85-100
Exclusion Criteria
  • More than one antihypertensive medication
  • Beta blockers, angiotensin converting enzyme inhibitors or angiotensin receptor blockers
  • History of coronary artery disease, heart failure, stroke, angina or coronary revascularization
  • Kidney disease, defined as plasma creatinine > 1.5mg/dL
  • Diabetes, defined by insulin or oral hypoglycemic medication or blood sugar > 126mg/dL
  • Pulmonary disease, defined as chronic obstructive pulmonary disease, bronchitis, asthma, or use of inhaler
  • Upper respiratory infection during past 30 days
  • Medication that affects central nervous system function
  • Steroid use
  • Current pregnancy or lactation within past six months
  • Current birth control medication or hormone replacement therapy
  • Condition that in the judgment of the Principal Investigator is incompatible with the research study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Device Guided BreathingRESPeRATEIndividual breathing rate was determined from an expandable band around the torso connected to a commercially available device (RESPeRATE, Lod, Israel) that presented distinctive tones via earphones.
Control GroupGuided BreathingControl group were instructed to sit in the same manner passively attend to their breathing, and silently repeat 'one' during each exhalation. If other thoughts came to mind, they were instructed to calmly attend to their breathing.
Primary Outcome Measures
NameTimeMethod
Breathing RateAfter 15 minutes of guided breathing or control task

Breathing rate was monitored continuously via inductive plethysmography.

Secondary Outcome Measures
NameTimeMethod
Minute VentilationAfter 15 minutes of guided breathing or control task

Minute Ventilation was continuously monitored via inductive plethysmography

End Tidal CO2 (PetCO2)After 15 minutes of guided breathing or control task

End tidal CO2 was monitored continuously using a respiratory gas monitor

Trial Locations

Locations (1)

NIA Clinical Research Unit

🇺🇸

Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath